Last reviewed · How we verify
Nabilone, flexible dosing
Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to modulate pain, nausea, and other symptoms.
Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to modulate pain, nausea, and other symptoms. Used for Chemotherapy-induced nausea and vomiting (CINV), Chronic pain conditions.
At a glance
| Generic name | Nabilone, flexible dosing |
|---|---|
| Also known as | Cesamet |
| Sponsor | University of Calgary |
| Drug class | Synthetic cannabinoid |
| Target | CB1 and CB2 cannabinoid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management, Oncology (chemotherapy-induced nausea and vomiting) |
| Phase | Phase 3 |
Mechanism of action
Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, which are distributed throughout the brain and peripheral tissues. By activating these receptors, it modulates neurotransmitter release and reduces pain signaling, nausea, and other symptoms. The flexible dosing approach allows individualized titration to optimize therapeutic benefit while minimizing adverse effects.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Chronic pain conditions
Common side effects
- Dizziness
- Drowsiness
- Dry mouth
- Euphoria or dysphoria
- Ataxia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nabilone, flexible dosing CI brief — competitive landscape report
- Nabilone, flexible dosing updates RSS · CI watch RSS
- University of Calgary portfolio CI